Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
This study assesses the efficacy and safety of olmesartan medoxomil in children ages 1-16
with high blood pressure. After a 5-week blinded treatment period of up to 5 weeks
participants can continue to take olmesartan medoxomil (OM) for up to an additional 46 weeks.